Abstract library

6 results for "Berthon".
#1628 What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis
Introduction: Patient-centered care means identifying what matters most through shared decision making. EVIDEM provides an MCDA platform to explore decision criteria and tradeoffs.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Dima Samaha
#1629 To Treat or Watch? Identifying Drivers of Decisions for Patients with GEP-NET Using Reflective Multi-Criteria Decision Analysis
Introduction: Somatostatin analogs (SSAs) or watchful-waiting are recommended for unresectable, well- or moderately-differentiated non-functioning GEP-NET.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Dima Samaha
#1648 Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad
#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)
Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt
#2105 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt
#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt